View ValuationMoberg Pharma 将来の成長Future 基準チェック /56Moberg Pharmaは、100.9%と63.3%でそれぞれ年率100.9%で利益と収益が成長すると予測される一方、EPSはgrowで100.9%年率。主要情報100.9%収益成長率100.90%EPS成長率Pharmaceuticals 収益成長14.6%収益成長率63.3%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日13 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 23Moberg Pharma AB (Publ) Approves the Election of Board MembersOn May 21, 2026. Moberg Pharma AB (publ) held its Annual General Meeting. The Annual General Meeting resolved, in accordance with the proposal of the shareholder Noster Capital Master Fund Limited ("Noster Capital"), on election of Lars Johansson, Jack Bradley and Daniel Kaufman as board members, all for the period until the end of the next Annual General Meeting. Lars Johansson was elected, in accordance with the proposal of both the Nomination Committee and Noster Capital, as the new Chairman of the Board for the period until the end of the next Annual General Meeting. Lars Johansson, born 1966, has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB. Lars Johansson holds no shares in the Company and is independent in relation to the Company, its management, and major shareholders.Jack Bradley, born 1991, has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen. Jack Bradley holds no shares in the Company, but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the Company, its management, and major shareholders.Daniel Kaufman, born 1968, has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc. (HROW), Delcath Systems Inc. (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy. Daniel Kaufman holds 1 409 456 shares in the Company and is independent in relation to the Company, its management, and major shareholders.お知らせ • Apr 18Moberg Pharma AB (Publ) Announces Board Members Not Standing for Re-ElectionsMoberg Pharma AB (publ) announced that Jonas Ekblom, Otto Skolling and Nikolaj Sørensen have informed the nomination committee that they are not available for re-election at its Annual General Meeting to be held on May 21, 2026.お知らせ • Mar 13Moberg Pharma AB Secures Additional Terbinafine Supplier For Mob-015Moberg Pharma AB announced that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed. As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient.お知らせ • Nov 28+ 3 more updatesMoberg Pharma AB (publ) to Report Q2, 2026 Results on Aug 13, 2026Moberg Pharma AB (publ) announced that they will report Q2, 2026 results on Aug 13, 2026お知らせ • Oct 31Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026.お知らせ • Sep 30Moberg Pharma AB (publ) Approves Board ElectionsMoberg Pharma AB (publ) at its Extraordinary General Meeting held on September 29, 2025 approved the election of Fredrik Blom and Mona Zhang as new members of the Board of Directors for the period until the end of the next Annual General Meeting. Thus, the Board of Directors of the Company will, for the period until the next Annual General Meeting, consist of Jonas Ekblom (chairman of the board of directors), Nikolaj Sörensen, Isabelle Ducellier, Otto Skolling, Richard Ding, Fredrik Blom and Mona Zhang.Mona Zhang was born in 1981 and holds an MBA from Rotman and a bachelor's degree in electrical engineering from Beijing Institute of Technology. Mona Zhang has more than 15 years of experience in global investment management and corporate governance. Mona is the Founder and Managing Partner of Trunity Partners Ltd., a portfolio management firm registered with the Ontario Securities Commission in Canada, where she is responsible for capital allocation, operations, and compliance. Previously, she worked at Mackenzie Investments as a Portfolio Manager on the Global Equity and Income Team, focusing on investment research, portfolio construction, and risk oversight. Earlier in her career, she was with Burgundy Asset Management, specializing in international equity analysis. Today, Mona serves on the Boards of the Canadian Business History Association and the International Agama Zen Practice Centre. She is also a guest lecturer at the Rotman School of Management, University of Toronto. She is a CFA charterholder. Mona holds no shares in the Company as of the day of this notice and is independent in relation to the Company, its management and major shareholders.Fredrik Blom was born in 1970 and holds a master's degree in financial economics from Stockholm University. Throughout his professional career, Fredrik has primarily worked in sales, often within entrepreneurially driven companies. He has co-founded several companies, one of them is Svenska Studenthus, a real estate company focused on rental and student housing, which merged with K2A Fastigheter prior to the company's IPO on Nasdaq Stockholm in 2019. Fredrik has extensive experience in starting companies and developing their initial cash flows. Other companies Fredrik has co-founded and served on the board of include Jeff Fastigheter and RAW Properties. Fredrik holds 926,000 shares in the Company, directly and indirectly, as of the day of this notice. Fredrik is independent in relation to the Company, its management and major shareholders.お知らせ • Jun 25Moberg Pharma AB (Publ) Announces Management ChangesMoberg Pharma AB (publ) announced that in connection with the reorganization, Anders Bröijersén, Chief Medical Officer, and Robert Ehrl, Head of Supply, are leaving Moberg Pharma and the management team. Going forward, supply is incorporated into Christina Erixon's existing area of responsibility. The company's medical expertise is secured through consultants. Following these changes, Moberg Pharma's management team consists of Anna Ljung, Mark Beveridge, Annica Magnusson, and Christina Erixon.お知らせ • Dec 18Moberg Pharma AB (Publ) Secures New Terbinafine SupplierMoberg Pharma AB (publ) announces that a new terbinafine supplier has been secured for MOB-015 (drug for nail fungus). As a result, terbinafine availability is no longer a limiting factor for the company's launch plans. Over the past year, Moberg Pharma qualified a new terbinafine manufacturer with an authorized EU Certificate of Suitability (CEP) now available for MOB-015. Three product batches have been produced using terbinafine from the new supplier where available stability data confirm the shelf-life profile of MOB-015. The status is unchanged for the previously communicated approval process regarding the first additional terbinafine supplier, submitted in April. Moberg Pharma has earlier responded to all questions received from the Medical Products Agency and awaits the agency´s decision. As a result, Moberg Pharma expects to have several alternate terbinafine suppliers secured in the near future. Each of these suppliers has the capacity to meet the company's global terbinafine demand.お知らせ • Nov 08Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025.お知らせ • Oct 23+ 2 more updatesMoberg Pharma AB (publ) to Report First Half, 2025 Results on Aug 12, 2025Moberg Pharma AB (publ) announced that they will report first half, 2025 results on Aug 12, 2025お知らせ • Oct 11Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025Moberg Pharma AB (publ) announced that they will report fiscal year 2024 results on Feb 11, 2025お知らせ • Sep 13Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail FungusMoberg Pharma AB (publ) announced that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact. The North American Phase 3 study is ongoing at 33 study centers in the US and Canada, including a total of 384 patients. The study constitutes an essential part of the clinical data required for the registration and commercialization of MOB-015 in the US and differs from previous studies with MOB-015, which is the basis for drug approval in 13 EU countries, by reducing the dosage - 8 weeks daily dosing followed by weekly maintenance treatment for 40 weeks, compared to daily dosing throughout the entire treatment period. In the process of preparing the database for upcoming topline data, the company has received information regarding clinical cure in a subset of patients in the study. Clinical cure is one of three parameters that together constitute the study's primary treatment goal, complete cure. All three parameters; clinical cure, negative fungal culture, and negative microscopy, need to be met for a patient to be considered completely cured. No information has been obtained about the other study parameters included in complete cure. The information obtained is blinded; no information has been received regarding which patient received active treatment or how many patients in the data subset received active treatment (patients in the study are randomized 2:1 to treatment with MOB-015 and vehicle). The total number of patients who have achieved clinical cure in this subset of patients is lower than the company's expectations, and Moberg Pharma assesses that the risk of not being able to commercialize the product in the US based on this study has significantly increased, which requires the company to inform the market of this fact. It is an absolute priority to protect the integrity of the study data, both as not to undermine the possibilities of using study results in discussions with regulatory authorities, and as there are patients with ongoing treatment in the study. Moberg Pharma will not speculate on possible outcomes or what this means for the future potential of MOB-015 and will await topline results to avoid drawing premature conclusions.お知らせ • May 16Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board MemberMoberg Pharma AB (publ) at its Annual General Meeting held on May 14, 2024, approved the election of Jonas Ekblom as board member for a period until the end of the next Annual General Meeting.お知らせ • May 08Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized ProcedureMoberg Pharma AB announced that MOB-015 has received national approvals for all countries included in the decentralized procedure. MOB-015 is thus approved for the treatment of mild to moderate fungal infections of the nails in adults in 13 European countries. National approvals follow the completion of the decentralized procedure with a positive result where MOB-015 is recommended for approval in 13 European countries. The following EU countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. MOB-015 can be obtained with a prescription (Rx) in the Czech Republic, Denmark, Finland, France, Ireland and Spain, while it's approved as a non-prescription medicinal product, i.e. over-the-counter (OTC) in Austria, Belgium, Hungary, Italy, the Netherlands, Norway and Sweden.お知らせ • Aug 04+ 2 more updatesMoberg Pharma AB (publ) to Report Nine Months, 2024 Results on Nov 12, 2024Moberg Pharma AB (publ) announced that they will report nine months, 2024 results on Nov 12, 2024業績と収益の成長予測OTCPK:MBGP.F - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20289527N/A34112/31/2027569N/A15112/31/202623-18N/A-1613/31/202615-26-45-12N/A12/31/202514-27-61-17N/A9/30/202512-258-71-16N/A6/30/202512-255-80-14N/A3/31/202513-251-92-21N/A12/31/202410-255-90-16N/A9/30/20249-18-115-27N/A6/30/20245-23-134-33N/A3/31/20241-23-139-31N/A12/31/2023N/A-21-157-33N/A9/30/2023N/A-18-134-29N/A6/30/20230-16-105-21N/A3/31/20230-16-96-16N/A12/31/20220-16-85-17N/A9/30/20220-17-75-14N/A6/30/2022N/A-16-70-12N/A3/31/2022N/A-16-56-7N/A12/31/2021N/A-16-47-15N/A9/30/2021348-44-9N/A6/30/2021347-46-12N/A3/31/2021345-58-16N/A12/31/2020347-52-10N/A6/30/20205020-474N/A6/30/201931-8N/A-76N/A3/31/201945531N/A88N/A12/31/20185-28N/A74N/A9/30/20183419N/A87N/A6/30/201834019N/A109N/A3/31/20183346N/A68N/A12/31/201743911N/A54N/A9/30/2017438-1N/A30N/A6/30/20174340N/A-44N/A3/31/201736935N/A-17N/A12/31/201633433N/A-18N/A9/30/201629936N/A-21N/A6/30/201626132N/A12N/A3/31/20162829N/A32N/A12/31/201528626N/A31N/A9/30/201527625N/A34N/A6/30/201526020N/A30N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MBGP.Fは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。収益対市場: MBGP.F今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: MBGP.F今後 3 年以内に収益を上げることが予想されます。収益対市場: MBGP.Fの収益 ( 63.3% ) US市場 ( 11.2% ) よりも速いペースで成長すると予測されています。高い収益成長: MBGP.Fの収益 ( 63.3% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MBGP.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/05 04:28終値2026/06/02 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Moberg Pharma AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Bjorn RydellABG Sundal Collier SponsoredKlas PykNordea MarketsMats HyttingeRedeye1 その他のアナリストを表示
お知らせ • May 23Moberg Pharma AB (Publ) Approves the Election of Board MembersOn May 21, 2026. Moberg Pharma AB (publ) held its Annual General Meeting. The Annual General Meeting resolved, in accordance with the proposal of the shareholder Noster Capital Master Fund Limited ("Noster Capital"), on election of Lars Johansson, Jack Bradley and Daniel Kaufman as board members, all for the period until the end of the next Annual General Meeting. Lars Johansson was elected, in accordance with the proposal of both the Nomination Committee and Noster Capital, as the new Chairman of the Board for the period until the end of the next Annual General Meeting. Lars Johansson, born 1966, has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB. Lars Johansson holds no shares in the Company and is independent in relation to the Company, its management, and major shareholders.Jack Bradley, born 1991, has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen. Jack Bradley holds no shares in the Company, but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the Company, its management, and major shareholders.Daniel Kaufman, born 1968, has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc. (HROW), Delcath Systems Inc. (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy. Daniel Kaufman holds 1 409 456 shares in the Company and is independent in relation to the Company, its management, and major shareholders.
お知らせ • Apr 18Moberg Pharma AB (Publ) Announces Board Members Not Standing for Re-ElectionsMoberg Pharma AB (publ) announced that Jonas Ekblom, Otto Skolling and Nikolaj Sørensen have informed the nomination committee that they are not available for re-election at its Annual General Meeting to be held on May 21, 2026.
お知らせ • Mar 13Moberg Pharma AB Secures Additional Terbinafine Supplier For Mob-015Moberg Pharma AB announced that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed. As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient.
お知らせ • Nov 28+ 3 more updatesMoberg Pharma AB (publ) to Report Q2, 2026 Results on Aug 13, 2026Moberg Pharma AB (publ) announced that they will report Q2, 2026 results on Aug 13, 2026
お知らせ • Oct 31Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026.
お知らせ • Sep 30Moberg Pharma AB (publ) Approves Board ElectionsMoberg Pharma AB (publ) at its Extraordinary General Meeting held on September 29, 2025 approved the election of Fredrik Blom and Mona Zhang as new members of the Board of Directors for the period until the end of the next Annual General Meeting. Thus, the Board of Directors of the Company will, for the period until the next Annual General Meeting, consist of Jonas Ekblom (chairman of the board of directors), Nikolaj Sörensen, Isabelle Ducellier, Otto Skolling, Richard Ding, Fredrik Blom and Mona Zhang.Mona Zhang was born in 1981 and holds an MBA from Rotman and a bachelor's degree in electrical engineering from Beijing Institute of Technology. Mona Zhang has more than 15 years of experience in global investment management and corporate governance. Mona is the Founder and Managing Partner of Trunity Partners Ltd., a portfolio management firm registered with the Ontario Securities Commission in Canada, where she is responsible for capital allocation, operations, and compliance. Previously, she worked at Mackenzie Investments as a Portfolio Manager on the Global Equity and Income Team, focusing on investment research, portfolio construction, and risk oversight. Earlier in her career, she was with Burgundy Asset Management, specializing in international equity analysis. Today, Mona serves on the Boards of the Canadian Business History Association and the International Agama Zen Practice Centre. She is also a guest lecturer at the Rotman School of Management, University of Toronto. She is a CFA charterholder. Mona holds no shares in the Company as of the day of this notice and is independent in relation to the Company, its management and major shareholders.Fredrik Blom was born in 1970 and holds a master's degree in financial economics from Stockholm University. Throughout his professional career, Fredrik has primarily worked in sales, often within entrepreneurially driven companies. He has co-founded several companies, one of them is Svenska Studenthus, a real estate company focused on rental and student housing, which merged with K2A Fastigheter prior to the company's IPO on Nasdaq Stockholm in 2019. Fredrik has extensive experience in starting companies and developing their initial cash flows. Other companies Fredrik has co-founded and served on the board of include Jeff Fastigheter and RAW Properties. Fredrik holds 926,000 shares in the Company, directly and indirectly, as of the day of this notice. Fredrik is independent in relation to the Company, its management and major shareholders.
お知らせ • Jun 25Moberg Pharma AB (Publ) Announces Management ChangesMoberg Pharma AB (publ) announced that in connection with the reorganization, Anders Bröijersén, Chief Medical Officer, and Robert Ehrl, Head of Supply, are leaving Moberg Pharma and the management team. Going forward, supply is incorporated into Christina Erixon's existing area of responsibility. The company's medical expertise is secured through consultants. Following these changes, Moberg Pharma's management team consists of Anna Ljung, Mark Beveridge, Annica Magnusson, and Christina Erixon.
お知らせ • Dec 18Moberg Pharma AB (Publ) Secures New Terbinafine SupplierMoberg Pharma AB (publ) announces that a new terbinafine supplier has been secured for MOB-015 (drug for nail fungus). As a result, terbinafine availability is no longer a limiting factor for the company's launch plans. Over the past year, Moberg Pharma qualified a new terbinafine manufacturer with an authorized EU Certificate of Suitability (CEP) now available for MOB-015. Three product batches have been produced using terbinafine from the new supplier where available stability data confirm the shelf-life profile of MOB-015. The status is unchanged for the previously communicated approval process regarding the first additional terbinafine supplier, submitted in April. Moberg Pharma has earlier responded to all questions received from the Medical Products Agency and awaits the agency´s decision. As a result, Moberg Pharma expects to have several alternate terbinafine suppliers secured in the near future. Each of these suppliers has the capacity to meet the company's global terbinafine demand.
お知らせ • Nov 08Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025.
お知らせ • Oct 23+ 2 more updatesMoberg Pharma AB (publ) to Report First Half, 2025 Results on Aug 12, 2025Moberg Pharma AB (publ) announced that they will report first half, 2025 results on Aug 12, 2025
お知らせ • Oct 11Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025Moberg Pharma AB (publ) announced that they will report fiscal year 2024 results on Feb 11, 2025
お知らせ • Sep 13Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail FungusMoberg Pharma AB (publ) announced that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact. The North American Phase 3 study is ongoing at 33 study centers in the US and Canada, including a total of 384 patients. The study constitutes an essential part of the clinical data required for the registration and commercialization of MOB-015 in the US and differs from previous studies with MOB-015, which is the basis for drug approval in 13 EU countries, by reducing the dosage - 8 weeks daily dosing followed by weekly maintenance treatment for 40 weeks, compared to daily dosing throughout the entire treatment period. In the process of preparing the database for upcoming topline data, the company has received information regarding clinical cure in a subset of patients in the study. Clinical cure is one of three parameters that together constitute the study's primary treatment goal, complete cure. All three parameters; clinical cure, negative fungal culture, and negative microscopy, need to be met for a patient to be considered completely cured. No information has been obtained about the other study parameters included in complete cure. The information obtained is blinded; no information has been received regarding which patient received active treatment or how many patients in the data subset received active treatment (patients in the study are randomized 2:1 to treatment with MOB-015 and vehicle). The total number of patients who have achieved clinical cure in this subset of patients is lower than the company's expectations, and Moberg Pharma assesses that the risk of not being able to commercialize the product in the US based on this study has significantly increased, which requires the company to inform the market of this fact. It is an absolute priority to protect the integrity of the study data, both as not to undermine the possibilities of using study results in discussions with regulatory authorities, and as there are patients with ongoing treatment in the study. Moberg Pharma will not speculate on possible outcomes or what this means for the future potential of MOB-015 and will await topline results to avoid drawing premature conclusions.
お知らせ • May 16Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board MemberMoberg Pharma AB (publ) at its Annual General Meeting held on May 14, 2024, approved the election of Jonas Ekblom as board member for a period until the end of the next Annual General Meeting.
お知らせ • May 08Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized ProcedureMoberg Pharma AB announced that MOB-015 has received national approvals for all countries included in the decentralized procedure. MOB-015 is thus approved for the treatment of mild to moderate fungal infections of the nails in adults in 13 European countries. National approvals follow the completion of the decentralized procedure with a positive result where MOB-015 is recommended for approval in 13 European countries. The following EU countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. MOB-015 can be obtained with a prescription (Rx) in the Czech Republic, Denmark, Finland, France, Ireland and Spain, while it's approved as a non-prescription medicinal product, i.e. over-the-counter (OTC) in Austria, Belgium, Hungary, Italy, the Netherlands, Norway and Sweden.
お知らせ • Aug 04+ 2 more updatesMoberg Pharma AB (publ) to Report Nine Months, 2024 Results on Nov 12, 2024Moberg Pharma AB (publ) announced that they will report nine months, 2024 results on Nov 12, 2024